Navigation Links
Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
Date:9/26/2007

BEIJING and CLAREMONT, Calif., Sept. 26 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) today announced that its wholly owned subsidiary, Kiwa Bio-Tech Products (Shandong) Co., Ltd., has completed the first stage of the planned upgrading of its manufacturing facility. Upgrades included building and equipping a fertilizer production line, and installing fermentation equipment for Bacillus.

In April Kiwa announced that the Shandong Provincial Soil and Fertilizer Station authorized Kiwa (Shandong)'s application and registration for two fertilizer registration certificates including one for a water flush fertilizer (applied to plants by mixing with water.)

Earlier this month Kiwa announced that the China Green Food Association of the Agriculture Ministry ("CGFA") has certified six Kiwa bio-fertilizer products as "Green Food CGFA Recommend Brands."

Mr. Wei Li, Chairman and CEO of Kiwa, stated, "With the completion of this stage of the fertilizer manufacturing facility upgrade, the installment of Bacillus fermentation equipment and the registrations of the patents we acquired from Chinese Agriculture University we will be able to better control product quality and significantly improve the competitive advantages of our products."

About Kiwa Bio-Tech Products Group Corporation

The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company's products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please visit the Company's website at http://www.kiwabiotech.com .

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

For more information, please contact:

Kiwa Bio-Tech Products Group Corporation

Yvonne Wang

Tel: +1-626-715-5855

Email: kiwabiotech@gmail.com

Robert Schechter

Equity Communications

Tel: +1-212-499-6809 or +1-646-234-3624

Email: ir4kiwa@hotmail.com


'/>"/>
SOURCE Kiwa Bio-Tech Products Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Industry Veterans take a look back from 2025: Bio-Technology, and Bio-Informatics are the focus
2. Sonic Foundry completes $11.25M stock offer
3. Orion Energy completes $5M capital round
4. RedPrairie completes MARC acquisition
5. Metavante completes purchase of check processing firm
6. GE completes $1.2 billion acquisition
7. M & Is Metavante completes Brasfield Corp. acquisition
8. Metavante completes GHR Systems acquisition
9. Metavante completes TREEV acquisition
10. Johnson Controls completes sale of French unit
11. OpGen completes $5 million investment round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):